FDA-cleared profile

NAEOTOM Alpha

Siemens Medical Solutions USA, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.

Clinical role
Photon-counting CT acquisition, reconstruction, spectral imaging, diagnostic review, and treatment or interventional imaging support.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: NAEOTOM Alpha does not support radiation therapy planning. The CT system is not the principal means of guidance in invasive procedures; needle orientation, needle advance, and handling are under the physician's control.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: X-ray projection data acquired by the photon-counting detector using supported protocols.
  • Who uses it?Intended users: Qualified CT technologists and physicians trained in diagnostic and interventional CT workflows.
  • What does the software produce?Output: Cross-sectional CT images, spectral or quantitative image sets, and examination information.
  • What is its most important limitation?Key limitation: NAEOTOM Alpha does not support radiation therapy planning. The CT system is not the principal means of guidance in invasive procedures; needle orientation, needle advance, and handling are under the physician's control.

Clinical takeaway. Clinical role: NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.

Evidence takeaway. Evidence from the reviewed source record: K233657 describes manufacturer image-quality, dose, spectral, reconstruction, safety, software, and workflow verification. Peer-reviewed photon-counting CT literature supplies technology-level clinical context but should remain separate from exact-release claims.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
NAEOTOM Alpha with syngo CT VB10 provides photon-counting CT for diagnosis, treatment and interventional support, and approved low-dose lung screening; this submission explicitly does not support radiation-therapy planning.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Photon-counting CT acquisition, reconstruction, spectral imaging, diagnostic review, and treatment or interventional imaging support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
X-ray projection data acquired by the photon-counting detector using supported protocols.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Cross-sectional CT images, spectral or quantitative image sets, and examination information.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Hospital and outpatient CT and interventional imaging departments.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified CT technologists and physicians trained in diagnostic and interventional CT workflows.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
NAEOTOM Alpha does not support radiation therapy planning. The CT system is not the principal means of guidance in invasive procedures; needle orientation, needle advance, and handling are under the physician's control.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet directly states the radiation-therapy-planning exclusion and invasive-procedure guidance limitation; the product-family literature caveat is not packet text.

Evidence summary
K233657 describes manufacturer image-quality, dose, spectral, reconstruction, safety, software, and workflow verification. Peer-reviewed photon-counting CT literature supplies technology-level clinical context but should remain separate from exact-release claims.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K233657 describes manufacturer image-quality, dose, spectral, reconstruction, safety, software, and workflow verification. Peer-reviewed photon-counting CT literature supplies technology-level clinical context but should remain separate from exact-release claims.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K233657 FDA performance package for NAEOTOM Alpha

  • DesignManufacturer bench, phantom, image-quality, dose, reconstruction, safety, software, and workflow validation
  • PopulationRepresentative head and body diagnostic, screening, treatment, and interventional CT protocols
  • Scopeexact submission
  • Tested versionNAEOTOM Alpha with syngo CT VB10
  • IndependenceSponsor or vendor study

K233657

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Clinical photon-counting CT experience and applications

  • DesignPeer-reviewed clinical technology review and experience report
  • PopulationPatients imaged with clinical photon-counting CT systems
  • Scopeproduct family
  • Tested versionPhoton-counting CT technology and NAEOTOM product family
  • IndependenceIndependent study

PMID 37602816

Technology-level evidence; K233657 explicitly excludes radiation-therapy planning.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K233657 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray projection data acquired by the photon-counting detector using supported protocols.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K233657: NAEOTOM Alpha

  2. Routing

    Source context, not route validation: DICOM CT workflow with advanced image objects; validate PACS, RIS, worklist, quantitative consistency, reconstruction, and downstream software support.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K233657: NAEOTOM Alpha · NAEOTOM Alpha photon-counting CT family · Clinical photon-counting CT experience and applications

  3. AI processing

    Source context, not route validation: Installed photon-counting CT system with syngo CT VB10 and corresponding detector, reconstruction, siting, and service infrastructure.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K233657: NAEOTOM Alpha · NAEOTOM Alpha photon-counting CT family · Clinical photon-counting CT experience and applications

  4. Returned objects

    Source context, not route validation: Cross-sectional CT images, spectral or quantitative image sets, and examination information.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K233657: NAEOTOM Alpha

  5. Viewer/worklist/report

    Unresolved route: Cross-sectional CT images, spectral or quantitative image sets, and examination information.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K233657: NAEOTOM Alpha

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed photon-counting CT system with syngo CT VB10 and corresponding detector, reconstruction, siting, and service infrastructure.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM CT workflow with advanced image objects; validate PACS, RIS, worklist, quantitative consistency, reconstruction, and downstream software support.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.

Training
Only qualified ct technologists and physicians trained in diagnostic and interventional ct workflows. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: K233657 explicitly does not support radiation-therapy planning, unlike K243523. The scanner is not the principal guidance method for invasive procedures, and product-family literature does not establish every exact-version outcome.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K233657 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM CT workflow with advanced image objects; validate PACS, RIS, worklist, quantitative consistency, reconstruction, and downstream software support.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. K233657 explicitly does not support radiation-therapy planning, unlike K243523. The scanner is not the principal guidance method for invasive procedures, and product-family literature does not establish every exact-version outcome.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: K233657 explicitly does not support radiation-therapy planning, unlike K243523. The scanner is not the principal guidance method for invasive procedures, and product-family literature does not establish every exact-version outcome.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233657
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-03-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
8Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 8 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 8 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

9 sources - 3 history items

Source ledger

  1. FDA K233657: NAEOTOM Alpha

    U.S. Food and Drug Administration - Published 2024-03-28 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. NAEOTOM Alpha photon-counting CT family

    Siemens Healthineers - Accessed 2026-09-03

    Scope: productFamily, workflowRole, implementationCapabilities, currentCommercialContext

  8. Clinical photon-counting CT experience and applications

    Radiology - Accessed 2026-09-03

    Scope: limitations, evidenceSummary, evidenceStudy, monitoring

  9. Siemens Healthineers: Cybersecurity

    Siemens Healthineers - Accessed 2026-10-26

    Scope: security

Research history

  1. K233657 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K243523

NAEOTOM Alpha.Peak/ NAEOTOM Alpha; NAEOTOM Alpha.Pro; NAEOTOM Alpha.Prime

Siemens Medical Solutions USA, Inc.

Authorized purpose: NAEOTOM Alpha.Peak, Alpha, Alpha.Pro, and Alpha.Prime are photon-counting CT systems for diagnostic cross-sectional imaging, treatment and interventional support, low-dose lung-cancer screening under approved protocols, and radiation-therapy planning.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2025-02-12
FDA-cleared K232491

CT 5300

Philips Healthcare (Suzhou) Co., Ltd.

CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2024-05-03

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history